Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PureTech HealthCHIX:PRTCL -0.83%61 Cash-to-Debt is 14.16 as of Dec. 2025, which is 5% above its 10-year median of 13.53. GuruFocus rates CHIX:PRTCL with a GF Score™ of 61/100 and a GF Value™ of £5.51 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,396 Biotechnology companies, PureTech Health ranks better than 58.02% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. PureTech Health's cash to debt ratio for the quarter that ended in Dec. 2025 was 14.16.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, PureTech Healthcould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for PureTech Health's Cash-to-Debt or its related term are showing as below:
CHIX:PRTCl'
s Cash-to-Debt Range Over the Past 10 Years
Min: 4.13 Med: 13.53 Max: 40.48
Current: 14.16
During the past 13 years, PureTech Health's highest Cash to Debt Ratio was 40.48. The lowest was 4.13. And the median was 13.53.
CHIX:PRTCl's Cash-to-Debt is ranked better than 58.02% of 1396
companies
in the Biotechnology industry
Industry Median: 7.175
vs CHIX:PRTCl: 14.16
PureTech Health (CHIX:PRTCl) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
PureTech Health Cash-to-Debt Related Terms
PureTech Health Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for PureTech Health's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CHIX:PRTCL vs VRTX, REGN, MRNA: Cash-to-Debt Comparison
For the Biotechnology subindustry, PureTech Health's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where PureTech Health's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PureTech Health (CHIX:PRTCL) has a Cash-to-Debt of 14.16 as of Dec. 2025. This is near median its historical median of 13.53. Over the past decade, PureTech Health's Cash-to-Debt has ranged from 4.13 to 40.48. According to the industry distribution chart, PureTech Health ranks #586 out of 1396 companies in the Biotechnology industry, placing it in the top 42%.
Is PureTech Health's Cash-to-Debt too high?
PureTech Health's current Cash-to-Debt of 14.16 is near median its 10-year median of 13.53. Over the past 10 years, this metric has ranged from a low of 4.13 to a high of 40.48. The Biotechnology industry median Cash-to-Debt is 7.18. PureTech Health's value of 14.16 is 97.4% above this industry median. Based on the distribution chart, PureTech Health ranks #586 out of 1396 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PureTech Health has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #586 out of 1396 companies for Cash-to-Debt. This puts PureTech Health in the upper half of its industry. The industry median Cash-to-Debt is 7.18. PureTech Health's value of 14.16 is 97.4% above this benchmark. Historically, PureTech Health's own Cash-to-Debt has ranged from 4.13 to 40.48 over the past decade. While the company's 10-year median is 13.53 vs. the industry median of 7.18, PureTech Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.18, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PureTech Health's current Cash-to-Debt of 14.16 is 97.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PureTech Health's current Cash-to-Debt is 14.16, which is near median its own 10-year median of 13.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (CHIX:PRTCL) is currently considered Possible Value Trap. The stock's GF Value™ is £5.51, compared to a current price of £1.20 — trading 78.3% below its estimated fair value. The current Cash-to-Debt is 14.16, which is near median its 10-year median of 13.53 and 97.4% above the Biotechnology industry median of 7.18. PureTech Health's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For PureTech Health (CHIX:PRTCL), the current Cash-to-Debt is 14.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (CHIX:PRTCL) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of £1.20 is trading 78.3% below its estimated GF Value™ of £5.51.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for CHIX:PRTCL:
Cash-to-Debt: 14.16 (near median its 10-year median of 13.53)
GF Value™: £5.51 vs. price of £1.20 (78.3% below fair value)
Industry Position: 97.4% above the Biotechnology median (#586 of 1396)
No single metric tells the full story. See the CHIX:PRTCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
61GF Score
Get the complete analysis for CHIX:PRTCL
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:PRTCL has been successfully added to your 
